Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib neoadjuvant treatment for locally advanced differentiated thyroid cancer
ChiCTR2300075973Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in well-differentiated thyroid cancer (WDTC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2300075973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075973.